Background: Transient tachypnea of the newborn (TTN) caused by lung edema resulting from delayed absorption of fetal alveolar lung fluid and is a common cause of admission of late preterm and full-term infants to neonatal intensive care units. Infant born by C-section and those with perinatal asphyxia, umbilical cord prolapse or certain maternal condition (asthma, diabetes, or analgesia) are more prone to develop TTN. Conventional treatment involves appropriate oxygen administration and continuous positive airway pressure in some cases. Hastening the clearance of lung liquid should shorten the duration of the symptoms and reduce complications. Objectives: This study aims to determine the effectiveness of inhaled budesonide in the treatment of this disorder through determining whether it reduces the duration of oxygen therapy and respiratory symptoms and shortens hospital stay in term infants with transient tachypnea of the newborn
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Enrollment
50
Budesonide 2 mL = 1000 microgram will be given within 6 hours of birth and the second dose will be given after 12 hours
Nebulized 0.9% saline will be given four times per day
Makassed General Hospital
Beirut, Lebanon
RECRUITINGAssessment of respiratory distress
Transient tachypnea of the newborn clinical score
Time frame: within 48 hours
Assessment of time to spontaneous breathing
Time to spontaneous unsupported breathing of room air (in hours)
Time frame: with 48 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.